[1] Global, regional,national incidence, prevalence,years lived with disabilityfor 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018,392(10159):1789-1858. [2] Cai A, Zheng C, Qiu J, et al.Prevalence of heart failure stages in the general population and implications for heart failure prevention: reports from the China Hypertension Survey 2012-15[J]. Eur J Prev Cardiol, 2023,30(13):1391-1400. [3] Bhatt D L, Verma S, Pitt B.EMPEROR-Preserved: A promise fulfilled[J]. Cell Metab, 2021,33(11):2099-2103. [4] Sun S, Joglar J A.Cardiac resynchronization therapy: prospect for long-lasting heart failure remission[J]. J Investig Med, 2011,59(6):887-892. [5] Linde C, Ellenbogen K, McAlister F A. Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations[J]. Heart Rhythm, 2012,9(8 Suppl):S3-S13. [6] O'Gara P T, Kushner F G, Ascheim D D, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013,61(4):e78-e140. [7] Pleger S T, Brinks H, Ritterhoff J, et al.Heart failure gene therapy: the path to clinical practice[J]. Circ Res, 2013,113(6):792-809. [8] Sanganalmath S K, Bolli R.Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions[J]. Circ Res, 2013,113(6):810-834. [9] Chen C, Hu Z, Liu S, et al.Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace[J]. Expert Opin Biol Ther, 2012,12(5):593-608. [10] Carve M, Allinson G, Nugegoda D, et al.Trends in environmental and toxicity research on organic ultraviolet filters: A scientometric review[J]. Sci Total Environ, 2021,773:145628. [11] Liu S, Sun Y P, Gao X L, et al.Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis[J]. Neural Regen Res, 2019,14(9):1643-1650. [12] SETTEL E.FURTHER EXPERIENCE WITH SPIRONOLACTONE-HYDRO-CHLOROTHIAZIDE (ALDACTAZIDE-A) IN THE LONG-TERM TREATMENT OF REFRACTORY CARDIAC EDEMA[J]. J Am Geriatr Soc, 1965,13:655-662. [13] Gray R, Chatterjee K, Vyden J K, et al.Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure[J]. Am Heart J, 1975,90(3):346-352. [14] 孙丽敏, 董绍臣, 刘宏丽, 等. 慢性阻塞性肺疾病并心力衰竭患者血清胆碱酯酶活性变化及其临床意义[J]. 中国实验诊断学, 2018,22(07):1140-1142. [15] 李阳, 霍建民. 慢性阻塞性肺疾病合并症的发病率及预后研究进展[J]. 临床肺科杂志, 2018,23(08):1527-1531. [16] BELIER G.Selecting patients with ischemic cardiomyopathy for medical treatment, revascularization, or heart transplantation[J]. Journal of Nuclear Cardiology, 1997,4(2):S152. [17] Williams T J, Snell G I.Early and long-term functional outcomes in unilateral, bilateral, and living-related transplant recipients[J]. Clin Chest Med, 1997,18(2):245-257. [18] Mullens W, Damman K, Testani J M, et al.Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2020,22(4):584-603. [19] Damman K, Testani J M.The kidney in heart failure: an update[J]. Eur Heart J, 2015,36(23):1437-1444. [20] Kitai T, Kirsop J, Tang W H.Exploring the Microbiome in Heart Failure[J]. Curr Heart Fail Rep, 2016,13(2):103-109. [21] 赵贤瑶. 基于引文新定义的引文微观测评方法研究[J]. 图书情报工作, 2010,54(20):139-143. [22] 王星, 刘伟. 基于引文的中文学术文献自动标引方法研究[J]. 图书情报工作, 2014,58(03):106-110. [23] Ponikowski P, Voors A A, Anker S D, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016,37(27):2129-2200. [24] Packer M, Bristow M R, Cohn J N, et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group[J]. N Engl J Med, 1996,334(21):1349-1355. [25] 侯小红. 大数据在国内知识产权方面的研究分析——基于核心期刊和CSSCI期刊的统计数据[J]. 中国发明与专利, 2022,19(10):62-70. [26] Pfeffer M A, Braunwald E, Moye L A, et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators[J]. N Engl J Med, 1992,327(10):669-677. [27] Lam M I, Chen P, Xie X M, et al.Heart failure and depression: A perspective from bibliometric analysis[J]. Front Psychiatry, 2023,14:1086638. [28] Mooney L, Hawkins N M, Jhund P S, et al.Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF[J]. J Am Heart Assoc, 2021,10(23):e021494. [29] Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2005,2005(4):CD003566. [30] Cruz D N, Schmidt-Ott K M, Vescovo G, et al. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI)[J]. Contrib Nephrol, 2013,182:117-136. [31] Wu M Z, Teng T K, Tay W T, et al.Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes[J]. Diabetes Obes Metab, 2023,25(3):707-715. [32] Marx N, Cheng A, Agarwal R, et al.Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe[J]. Eur Heart J Suppl, 2022,24(Suppl L):L29-L37. [33] 符珍珍, 彭瑜, 张钲. 射血分数超常的心力衰竭研究进展[J]. 中国急救医学, 2024,44(02):177-180. [34] Yancy C W, Jessup M, Bozkurt B, et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol, 2017,70(6):776-803. [35] 王天娇, 周琳, 刘一航, 等. 评估心力衰竭预后相关指标的研究进展[J]. 中国循证心血管医学杂志, 2017,9(03):374-376. [36] 朱明军, 毛静远, 张健. 慢性心力衰竭临床研究结局指标选择与应用专家共识[J]. 中医杂志, 2024,65(11):1196-1200. [37] 刘昭君, 周晓莉. 基于系统性炎症指标构建的列线图可预测心力衰竭患者的不良结局[J]. 南方医科大学学报, 2022,42(08):1149-1158. [38] Tsuji H, Larson M G, Jr V F, et al.Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study.[J]. Circulation, 1996,94(11):2850-2855. [39] Dekker J M, Crow R S, Folsom A R, et al. Low Heart Rate Variability in a 2-Minute Rhythm Strip Predicts Risk of Coronary Heart Disease and Mortality From Several Causes The ARIC Study[J]. Circulation, 2000(11). [40] Stein P K, Domitrovich P P, Huikuri H V, et al.Traditional and nonlinear heart rate variability are each independently associated with mortality after myocardial infarction.[J]. J Cardiovasc Electrophysiol, 2010,16(1):13-20. |